Integra Lifesciences Holdings (IART) Finished Goods (2010 - 2017)

Integra Lifesciences Holdings (IART) posted Finished Goods of $136.7 million for Q3 2017, up 6.84% sequentially from $128.0 million in Q4 2016.

Integra Lifesciences Holdings (IART) Finished Goods (2010 - 2017) Analysis & Trends

Integra Lifesciences Holdings has reported Finished Goods for 7 years, with the latest figure at $136.7 million in Q3 2017.

Quarterly Finished Goods changed N/A year-over-year to $136.7 million in Q3 2017, while the trailing twelve-month figure through Sep 2017 was $136.7 million (changed N/A YoY) and the FY2016 annual result came in at $128.0 million, changed N/A from the prior year.
Finished Goods advanced to $136.7 million in Q3 2017 per IART's latest filing, from $128.0 million in the prior quarter.
Over five years, Finished Goods peaked at $150.5 million in Q4 2014 and troughed at $128.0 million in Q4 2016.
A 4-year average of $140.5 million and a median of $141.8 million in 2015 frame the typical range for Finished Goods.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	202.72 Bn	197.12 Bn	7.27 Bn
2	Stryker	126.42 Bn	122.94 Bn	4.50 Bn
3	Medtronic	119.75 Bn	110.53 Bn	6.41 Bn
4	Boston Scientific	74.13 Bn	73.60 Bn	3.85 Bn
5	Edwards Lifesciences	51.78 Bn	47.53 Bn	1.35 Bn
6	Dexcom	35.29 Bn	33.34 Bn	830.00 Mn
7	GE HealthCare Technologies	33.95 Bn	31.85 Bn	2.18 Bn
8	Koninklijke Philips	26.22 Bn	22.90 Bn	4.55 Bn
9	Steris	23.21 Bn	22.73 Bn	684.20 Mn
10	Integra Lifesciences Holdings	1.29 Bn	1.02 Bn	219.74 Mn

Download Data